Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 65   

Articles published

ARNA 4.01 -0.09 (-2.20%)
price chart
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) Fights for Share of Weight-loss Pill ...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA, ARNA message board) is expected to launch its patented Belviq treatment early next year, but there are some doubts that by that time Vivus, Inc. (NASDAQ:VVUS) will have made its Qsymia something of a ...
Arena Pharmaceuticals, Vivus Inc, and the Weight-loss Craze
According to a Centers for Disease Control study earlier this year, about 36 percent of Americans are obese. While this might seem like an investing goldmine, biotech and small-cap pharmaceuticals are notoriously difficult companies to gauge. There are ...
Weight Loss Stocks In Action  Seeking Alpha
Ampio's Promising Pipeline Could Send Company Higher
The following charts of Arena Pharmaceuticals (NASDAQ:ARNA), Amarin Corp (NASDAQ:AMRN) and Vivus, Inc. (NASDAQ:VVUS) show how rapidly prices can rise in the year before an approval.
Heroes And Zeros: Arena Pharmaceuticals And Avanir Pharmaceuticals
Arena Pharmaceuticals is a clinical stage biopharmaceutical company that has discovered, developed, and moved the first anti-obesity drug through FDA approval in the last 13 years in June of 2012.
Arena: DEA Schedule IV Will Make Belviq The Obesity Blockbuster Drug
In addition, Arena comes with some enticing benefits for a pharmaceutical suitor - 10 year Swiss Tax Haven and R&D Write-offs.
500 Million Reasons to Bet on the Future of Mannkind (MNKD, ARNA,AMGN)
That is a huge show of strength for the diabetes drug developer operating in the biotech sector along with Amgen (NASDAQ: AMGN) and Arena Pharmaceuticals (NASDAQ: ARNA). As uber financier Mike Milken has pointed out, the ... that a good read was ...
Obesity Drugs Gain Attention on FDA Backing for Therapies
Third Rock Ventures is an early backer of Zafgen Inc., a biotechnology company in mid-stage trials of a therapy to treat obesity. The Food and Drug Administration cleared Belviq, from Arena Pharmaceuticals Inc. and Eisai Co., in June and Vivus Inc.'s ...
Vivus Shares Feel The Pain: Blockbuster Diet Drug Likely Won't Be Sold ...  Forbes
All Eyes On Vivus As Weight Loss Drug Hits Market  YCharts
Promentis receives grant to develop schizophrenia drugs
Milwaukee-based Promentis Pharmaceuticals Inc. has received a three-year, $1.8 million award from the National Institutes of Health to develop more effective drugs to treat schizophrenia.
Dr. Jean-Paul Castaigne, CEO of Angiochem
Yet the most exciting developments for Angiochem this year have been in the rare-diseases arena. The company raised its profile and brought publicity to its preclinical efforts in transporting enzyme drugs for orphan disorders into the brain in ...
The Rev. Sun Myung Moon to be laid to rest in South Korea
Prayers, singing, floral tributes and eulogies are expected as the remains of Moon arrive at the arena. After a two-hour ceremony, he will be laid to rest on Mount Cheonseong in the northern South Korean province of Gyeonggi -- known as the "holy land ...